Augmentation of natural killer cell-mediated anti-tumor effects by molecular targeting and regulatory T cell depletion.

More About This Textbook

Overview

Accumulating evidence indicates that the innate and adaptive immune systems make a crucial contribution to the anti-tumour effects of immunotherapy-based cancer treatments. We sought means to augment immune anti-tumor effector mechanisms through agents that target the cancer as well as means to promote immune effects. Bortezomib is a proteasome inhibitor that has direct anti-tumor effects. We and others have previously demonstrated that bortezomib could also sensitize tumor cells to killing via the death ligand, TRAIL. Natural killer (NK) cells represent a potent anti-tumor effector cell. Therefore we investigated whether bortezomib could sensitize tumor cells to NK cell-mediated killing. Pre-incubation of tumor cells with bortezomib had no effect on short-term NK cell killing or purified granule killing assays. Using a 24 hour lysis assay, increases in tumor killing was only observed using perforin-deficient NK cells. This increased killing was found to be dependent on both TRAIL and FasL, correlating with an increase in tumor expression of Fas and DR5. Long-term tumor outgrowth assays allowed for the detection of this increased tumor killing by activated NK cells following bortezomib treatment of the tumor. In a tumor purging assay, in which tumor:bone marrow cell mixtures were placed into lethally irradiated mice, only treatment of these mixtures with a combination of NK cells with bortezomib resulted in significant tumor-free survival of the recipients. These results demonstrate that bortezomib treatment can sensitize tumor cells to cellular effector pathways. Therefore, the combination of proteasome inhibition with immune therapy may result in increased anti-tumor efficacy. We are also interested in activating endogenous NK cells with IL-2. IL-2 has been extensively examined to promote clinical T and NK cell responses. Regulatory T cells (Tregs) have been shown to suppress many aspects of the immune system, including natural killer (NK) cell-mediated responses. In our study, we demonstrated that in vivo administration of IL-2 led to an activation and expansion of both NK cells and immunosuppressive Tregs. Therefore, we attempted to augment NK cell anti-tumor effects by concurrently depleting Tregs using anti-CD25. Increased NK cell activation by IL-2 correlated with an increase in classical, short-term NK cell killing in vitro regardless of depletion of Tregs. However, when splenocytes from treated mice were used in long-term tumor outgrowth assays, we observed that the combination of Treg depletion with IL-2 administration led to improved anti-tumor effects compared to either treatment alone. Importantly, these in vitro data correlated with in vivo survival of leukemia-bearing mice in which co-treatment of IL-2 with anti-CD25 led to significantly improved survival compared to mice treated with either IL-2 alone or Treg depletion. Prior depletion of NK1.1+ cells, but not CD8+ cells, completely abrogated all anti-tumor effects mediated by IL-2 and anti-CD25 combination therapy. These findings demonstrate that superior NK cell-mediated anti-leukemic effects can be achieved with IL-2 administration and concurrent depletion of CD25+ cells. Thus the combined therapies of not only sensitizing tumors by molecular targeting, but also stimulating immune responses as well as removing negative regulators may lead to powerful anti-tumor therapies.
Read More Show Less

Product Details

  • ISBN-13: 9780549568162
  • Publisher: ProQuest LLC
  • Sold by: Barnes & Noble
  • Format: eTextbook
  • Pages: 183
  • File size: 5 MB

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)